Hidradenitis suppurativa Janse, Ineke

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record

Publication date: 2016 Link to publication in University of Groningen/UMCG research database

Citation for published version (APA): Janse, I. C. (2016). Hidradenitis suppurativa: Pathogenesis, burden of disease and surgical strategies [Groningen]: Rijksuniversiteit Groningen

Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 29-01-2017

Hidradenitis suppurativa Pathogenesis, burden of disease and surgical strategies I.C. Janse, The Netherlands 2016

ISBN 978-90-367-8753-6 ISBN 978-90-367-8752-9 (e-book) Cover design: Jacqueline Pinkster Interior design: M.O, Wolf - MOTTOW - mottow.nl © Copyright 2016 I.C. Janse, The Netherlands All rights reserved. No part of this thesis may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage or retrieval system, without written permission of the author. The copyright of previously published chapters of this thesis remains with the publisher or journal.

Financial support for the publication of this thesis was provided by: Abbvie BV, ALK-Albelló BV, Celgene BV, Fagron BV, Galderma BV, Janssen-Cilag BV, La Roche-Posay, Leo Pharma BV, Rijksuniversiteit Groningen, Studiefonds Dermatologie, Universitair Medisch Centrum Groningen, Will Pharma BV.

HIDRADENITIS SUPPURATIVA PATHOGENESIS, BURDEN OF DISEASE AND SURGICAL STRATEGIES

Proefschrift

ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen op gezag van de rector magnificus prof. dr. E. Sterken en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op maandag 30 mei 2016 om 11:00 uur

door

Ineke Christina Janse geboren op 21 februari 1986 te Arnhem

Promotor Prof. dr. M.F. Jonkman

Copromotor Dr. B. Horváth

Beoordelingscommissie Prof. dr. C. Zouboulis Prof. dr. P.M.N. Werker Prof. dr. G. Dijkstra

CONTENTS Chapter 1

Introduction

11

Chapter 2

Identification of clinical and genetic parameters associated with

25

hidradenitis suppurativa in inflammatory bowel disease Chapter 3

Increased expression of integrin alpha6beta4 in the basement mem-

41

brane zone lining the sebaceous glands in hidradenitis suppurativa Chapter 4

Cytokeratin expression in epidermis and intact hair follicles of

51

patients with hidradenitis suppurativa Chapter 5

Sexual health and quality of life are severely impaired in hidradenitis

61

suppurativa: a multicenter cross-sectional study Chapter 6

Pain management in patients with hidradenitis suppurativa

73

Chapter 7

Hidradenitis suppurativa is associated with a low socioeconomic

83

status: a cross-sectional reference study Chapter 8

Skin-Tissue-sparing Excision with Electrosurgical Peeling (STEEP):

97

a case series in hidradenitis suppurativa Chapter 9

Surgical procedures in hidradenitis suppurativa

105

Chapter 10

General discussion and future perspectives

127

Chapter 11

Summary

139

Samenvatting

143

List of publications

148

Dankwoord

150

Curriculum Vitae

154

Appendices

LIST OF ABBREVIATIONS AMPs:

antimicrobial peptides

AGI:

anogenital involvement

ASEX:

arizona sexual experience scale

BMI:

body mass index

BMZ:

basement membrane zone

CI:

confidence interval

CK:

cytokeratin

CT:

computed tomography

CD:

crohn’s disease

CM:

centimetre

CO2:

carbon dioxide

COX2:

cyclooxygenase-2

DLQI:

dermatology life quality index

EDF:

European dermatology forum

FSFI:

female sexual function index

FPSU:

folliculopilosebaceous unit

GWAS:

genome-wide association studies

GS:

gamma-secretase

HF:

hair follicle

HS:

hidradenitis suppurativa

IASP:

international association for the study of pain

IBD:

inflammatory bowel disease

IF:

immunofluorescence

IFE:

interfollicular epidermis

IIEF:

international index of erectile function

INF:

infundibulum

IS:

isthmus

LD:

linkage disequilibrium

MRI:

magnetic resonance imaging

NCSTN:

nicastrin

NOD2:

nucleotide-binding oligomerization domain containing 2

NRS:

numerical rating scale

OR:

odds ratios

ORS:

outer root sheath

PAS:

periodic acid-Schiff

PCOS:

polycystic ovarian syndrome

PGA:

patient global assessment

PRR:

pattern-recognition receptors

PSEN1:

presenilin-1

PSENEN:

presenilin enhancer-2

QC:

quality control

QoL:

quality of life

RHS:

regular HS

SAPIR:

sexually active patients in a relationship

SAPNIR:

sexually active patients not in a relationship

SCC:

squamous cell carcinoma

SD:

standard deviation

SES:

socioeconomic status

SFJ:

sebofollicular junction

SG:

sebaceous gland

SIH:

secondary intention healing

SNRIs:

serotonin–norepinephrine reuptake inhibitors

SSRI:

selective serotonin reuptake inhibitors

STEEP:

skin-tissue-saving excision with electrosurgical peeling

TCWC:

time to complete wound closure

TLA:

tumescent local anesthesia

UC:

ulcerative colitis

10